NCT00416182View on ClinicalTrials.gov

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
SinusitisCystic Fibrosis
Interventions
DRUG

Pulmozyme (dornase alfa)

2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device

DRUG

Placebo

2.5 mL of placebo delivered via Sinustar nebulizer device

Trial Locations (1)

05401

Fletcher Allen Health Care, Burlington

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Vermont

OTHER